Autolus Therapeutics (NASDAQ:AUTL) Trading Up 8.9%

Share on StockTwits

Autolus Therapeutics Ltd – (NASDAQ:AUTL) was up 8.9% during trading on Friday . The stock traded as high as $15.30 and last traded at $13.50, approximately 292,800 shares traded hands during mid-day trading. An increase of 71% from the average daily volume of 170,856 shares. The stock had previously closed at $12.40.

Several equities research analysts recently commented on AUTL shares. William Blair reissued a “buy” rating on shares of Autolus Therapeutics in a report on Tuesday, September 3rd. Zacks Investment Research raised shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, July 11th. HC Wainwright reissued a “buy” rating and issued a $24.00 price target on shares of Autolus Therapeutics in a report on Thursday. Finally, ValuEngine raised shares of Autolus Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Autolus Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $37.00.

The company has a market cap of $529.93 million, a PE ratio of -9.51 and a beta of 0.61. The firm’s fifty day moving average is $12.15 and its 200 day moving average is $19.78. The company has a current ratio of 13.12, a quick ratio of 13.12 and a debt-to-equity ratio of 0.09.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.11. The company had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $2.00 million. As a group, sell-side analysts anticipate that Autolus Therapeutics Ltd – will post -3.11 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD boosted its stake in Autolus Therapeutics by 120.8% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,180,396 shares of the company’s stock worth $19,004,000 after purchasing an additional 645,879 shares during the last quarter. Marshall Wace LLP boosted its stake in Autolus Therapeutics by 121.3% during the 2nd quarter. Marshall Wace LLP now owns 515,405 shares of the company’s stock worth $8,298,000 after purchasing an additional 282,474 shares during the last quarter. Artal Group S.A. boosted its stake in Autolus Therapeutics by 11.1% during the 2nd quarter. Artal Group S.A. now owns 500,000 shares of the company’s stock worth $8,050,000 after purchasing an additional 50,000 shares during the last quarter. BlackRock Inc. boosted its stake in Autolus Therapeutics by 6.2% during the 2nd quarter. BlackRock Inc. now owns 200,872 shares of the company’s stock worth $3,234,000 after purchasing an additional 11,802 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its stake in Autolus Therapeutics by 126.3% during the 2nd quarter. Victory Capital Management Inc. now owns 95,560 shares of the company’s stock worth $1,539,000 after purchasing an additional 53,330 shares during the last quarter. 51.64% of the stock is currently owned by institutional investors.

Autolus Therapeutics Company Profile (NASDAQ:AUTL)

Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.

Read More: Is a Roth IRA right for you?

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.